Great Point Partners’s RAPT Therapeutics RAPT Stock Holding History

Great Point Partners’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-581,187	Closed	-$19.7M	–	47
2025 Q4	$19.7M	Buy	+581,187	New	+$18M	6.38%	5
2024 Q1	–	Sell	-137,469	Closed	-$27.3M	–	41
2023 Q4	$27.3M	Sell	137,469 -44,790	-25%	-$5.54M	4.66%	7
2023 Q3	$24.2M	Sell	182,259 -885	-0.5%	-$144K	4.41%	7
2023 Q2	$27.4M	Buy	183,144 +13,750	+8%	+$2.14M	5.36%	5
2023 Q1	$24.9M	Sell	169,394 -10,177	-6%	-$2.06M	4.88%	5
2022 Q4	$28.4M	Buy	179,571 +140,196	+356%	+$22.4M	5.58%	3
2022 Q3	$7.58M	Buy	+39,375	New	+$7.45M	1.82%	20

Great Point Partners's RAPT Position: Q1 2026 in Review

Great Point Partners sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 581,187 shares — an estimated $19.7M sold.

Great Point Partners first reported a position in RAPT in Q3 2022 and held it in 7 quarters. The position peaked at $28.4M in Q4 2022. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Great Point Partners reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Great Point Partners sold 581,187 RAPT Therapeutics shares in Q1 2026, an estimated $19.7M.
Great Point Partners first reported a position in RAPT Therapeutics in Q3 2022 and held it in 7 quarters.
Great Point Partners's RAPT Therapeutics position peaked at $28.4M in Q4 2022.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.